Bain Capital Public Equity Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bain Capital Public Equity Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-560,718	Closed	-$7.14M	–	59
2014 Q3	$7.14M	Sell	560,718 -952,682	-63%	-$14.4M	0.18%	52
2014 Q2	$34.2M	Hold	1,513,400	–	–	0.83%	43
2014 Q1	$42.8M	Buy	+1,513,400	New	+$56.2M	1.14%	34

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Public Equity Management's DRNA Position: Q4 2014 in Review

Bain Capital Public Equity Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2014, closing a stake of 560,718 shares — an estimated $7.14M sold.

Bain Capital Public Equity Management first reported a position in DRNA in Q1 2014 and held it in 3 quarters. The position peaked at $42.8M in Q1 2014. 47 funds tracked by Wall St. Rank hold DRNA as of Q4 2014.

Bain Capital Public Equity Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
Bain Capital Public Equity Management sold 560,718 Dicerna Pharmaceuticals, Inc. shares in Q4 2014, an estimated $7.14M.
Bain Capital Public Equity Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
Bain Capital Public Equity Management's Dicerna Pharmaceuticals, Inc. position peaked at $42.8M in Q1 2014.
47 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2014.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2014, filed 17 Feb 2015.